menu
    • menu
    [{"orgOrder":0,"company":"SENJU PHARMACEUTICAL CO LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Fonadelpar","moa":"Peroxisome proliferator-activated receptor delta","graph1":"Ophthalmology","graph2":"Phase III","graph3":"SENJU PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"SENJU PHARMACEUTICAL CO LTD \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SENJU PHARMACEUTICAL CO LTD \/ Undisclosed"},{"orgOrder":0,"company":"SENJU PHARMACEUTICAL CO LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Fonadelpar","moa":"Peroxisome proliferator-activated receptor delta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"SENJU PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"SENJU PHARMACEUTICAL CO LTD \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SENJU PHARMACEUTICAL CO LTD \/ Undisclosed"},{"orgOrder":0,"company":"SENJU PHARMACEUTICAL CO LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Fonadelpar","moa":"Peroxisome proliferator-activated receptor delta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"SENJU PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"SENJU PHARMACEUTICAL CO LTD \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SENJU PHARMACEUTICAL CO LTD \/ Undisclosed"},{"orgOrder":0,"company":"Eyenovia","sponsor":"SENJU PHARMACEUTICAL CO LTD","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Fonadelpar","moa":"Peroxisome proliferator-activated receptor delta","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eyenovia \/ SENJU PHARMACEUTICAL CO LTD","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ SENJU PHARMACEUTICAL CO LTD"}]

    Find Clinical Drug Pipeline Developments & Deals for Fonadelpar

    Menu

    Fonadelpar

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eyenovia

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Eyenovia

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fonadelpar

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : SENJU PHARMACEUTICAL CO LTD

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Eyenovia and Senju Pharmaceutical Sign Collaboration for Chronic Dry Eye Treatment

                            Details : both companies intend to work to develop Senju’s corneal epithelial candidate, SJP-0035, for use with Eyenovia’s Optejet dispensing technology, as a potential treatment for chronic dry eye disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 23, 2024

                            Lead Product(s) : Fonadelpar

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : SENJU PHARMACEUTICAL CO LTD

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SENJU PHARMACEUTICAL CO LTD

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SENJU PHARMACEUTICAL CO LTD

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fonadelpar

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease

                            Details : SJP-0035 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 17, 2018

                            Lead Product(s) : Fonadelpar

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SENJU PHARMACEUTICAL CO LTD

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SENJU PHARMACEUTICAL CO LTD

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fonadelpar

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Dis...

                            Details : SJP-0035 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Corneal Epithelial Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 11, 2016

                            Lead Product(s) : Fonadelpar

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SENJU PHARMACEUTICAL CO LTD

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SENJU PHARMACEUTICAL CO LTD

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fonadelpar

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epitheli...

                            Details : SJP-0035 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Corneal Epithelial Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 04, 2014

                            Lead Product(s) : Fonadelpar

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth